Senate vote puts ACA's device tax in doubt

Share this article:
Sen. Al Franken
Sen. Al Franken

An overwhelming Senate majority voted to repeal the device tax as a unified Republican minority was joined by a majority of Democrats, many representing states that are home to device firms.

Because the budget amendment they passed is nonbinding and Senate leadership remains in favor of the tax, nothing will come of it immediately, but in marking the law's vulnerability, the 79-20 vote is a big win for the device industry.

A 2.3% excise tax on revenues from medical device sales was included in the Affordable Care Act after device companies, unlike pharmas, declined to negotiate cost-savings to federal programs – effectively betting that healthcare reform would fail. That bet proved costly, and the industry has lobbied furiously to overturn the tax, which went into effect in January.

Advamed, the device industry trade group, has said the tax will cost manufacturers around $194 million per month and put 43,000 jobs in jeopardy. Stryker went as far as to say it would shutter two New York plants and lay off 5% of its workforce to offset the loss from the tax, which is meant to raise $29 billion over ten years. For comparison, pharmas committed to discounts and price cuts to federal programs worth nearly $100 billion in negotiations with Senate Democrats and the White House. However, the drug industry dwarfs devices, and those agreed-upon cost-savings largely go towards shoring up the Medicare Part D prescription drug benefit, a program pharmas favor, by filling in the “Donut hole.”

Among the device industry's champions in the Senate have been Minnesota's Amy Klobuchar and Al Franken, both Democrats. Minnesota is home to Medtronic and St. Jude Medical, among other device makers.

“The medical device industry has created tens of thousands of good-paying jobs in Minnesota and 400,000 nationwide and helps save countless lives every year," said Franken in a February statement. "I've fought against this tax since it was proposed. And I am cosponsoring this legislation to repeal the medical device tax so we can ensure that this important industry continues to create jobs and produce life-saving devices. I will fight to get this bill passed and to find a bipartisan offset to replace the revenue from the tax."

Sen. Orrin Hatch (R-UT), the legislation's lead sponsor, said in February: "Simply put, this is an anti-competitive tax that pulls the rug out from underneath American innovation and job creation. Whacking medical device manufacturers with a near $30 billion tax hike stifles the development of life-saving medical devices with high costs that will, ultimately, be passed on to consumers. It's just plain, bad policy and should be fully repealed."

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...